Insulet (NASDAQ:PODD) Downgraded by Wall Street Zen to Buy

Insulet (NASDAQ:PODD) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

A number of other analysts have also issued reports on PODD. Citigroup lowered their target price on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Robert W. Baird reduced their price target on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Jefferies Financial Group decreased their price objective on shares of Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Raymond James Financial set a $216.00 price objective on shares of Insulet in a research report on Monday, June 8th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $280.00 target price on shares of Insulet in a research note on Wednesday, May 27th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $238.67.

Insulet Price Performance

Shares of PODD stock opened at $158.25 on Friday. Insulet has a 52-week low of $138.79 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The firm has a market capitalization of $10.96 billion, a P/E ratio of 36.80, a P/E/G ratio of 1.07 and a beta of 1.13. The stock has a 50 day moving average price of $159.09 and a 200 day moving average price of $220.64.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the company posted $1.02 EPS. Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts predict that Insulet will post 6.46 earnings per share for the current year.

Insider Activity

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

Hedge funds have recently added to or reduced their stakes in the business. Basecamp Wealth Advisors LLC grew its holdings in Insulet by 48.3% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 102 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Insulet by 38.1% in the 1st quarter. Empowered Funds LLC now owns 2,880 shares of the medical instruments supplier’s stock valued at $604,000 after purchasing an additional 795 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of Insulet in the 1st quarter worth approximately $2,098,000. Glenmede Trust Co. NA lifted its position in shares of Insulet by 6.5% in the 1st quarter. Glenmede Trust Co. NA now owns 2,717 shares of the medical instruments supplier’s stock worth $570,000 after purchasing an additional 166 shares during the period. Finally, Essential Partners LLC boosted its stake in shares of Insulet by 9,980.0% during the first quarter. Essential Partners LLC now owns 504 shares of the medical instruments supplier’s stock valued at $106,000 after purchasing an additional 499 shares in the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.